The largest database of trusted experimental protocols

24 protocols using taqman snp genotyping

1

Genetic Profiling of Essential Tremor

Check if the same lab product or an alternative is used in the 5 most similar protocols
Consecutive patients with ET who presented to tertiary referral centres and examined by movement disorders neurologists were included. Patients satisfied the diagnostic criteria of classic ET based on the recommendations of the Consensus Statement of the Movement Disorders Society4 (link). Healthy individuals of similar gender, race and age were included as controls. Subjects with evidence of other neurodegenerative diseases were excluded. ET cases did not have evidence of thyroid dysfunction. Written informed consent from all the study subjects was obtained.
Genomic DNA was extracted from blood samples and LRRK2 c.4883G>C (R1628P; rs33949390) was genotyped by Taqman SNP genotyping (Life Technologies, Singapore). All positives and selected negatives were further confirmed by capillary/Sanger sequencing analysis with standard protocols. Our study was approved by the SingHealth Centralised Institutional Review Board (CIRB) and all the methods were carried out in accordance with the approved guidelines. Fisher's Exact Test for Count Data was used to compare the categorical and numerical variables. Statistical significance was defined at p < 0.05.
+ Open protocol
+ Expand
2

LRRK2 R1628P Genotyping Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood samples were collected from all participants for genotyping. DNA was extracted from the blood samples collected using Blood DNA Midi Kit (Qiagen, USA). LRRK2 c.4883aG > C (R1628P; rs33949390) was genotyped by Taqman SNP genotyping (Life Technologies, Singapore). All positives and selected negatives were confirmed by capillary/Sanger sequencing analysis.
+ Open protocol
+ Expand
3

Genetic Profiling from Blood Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood samples were collected from subjects and genotyped. DNA extraction was carried out using Blood DNA Midi Kit (Qiagen, USA) and genotyped by Taqman SNP genotyping (Life Technologies, Singapore). All positives and selected negatives were confirmed by capillary/Sanger sequencing analysis with standard protocol.
+ Open protocol
+ Expand
4

Genetic Profiling of AML Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols
Genomic DNA was extracted from peripheral blood taken on EDTA from 92 AML patients and 135 healthy individuals using a Qiagen DNA Isolation Kit (QIAGEN, Hilden, Germany). DNA was also isolated from AML cell lines. DNA purity and concentration were verified on the DeNovix DS-11 spectrophotometer (DeNovix Inc., Wilmington, DE, USA). Isolated DNA was subsequently stored at −20 °C until further use.
BSG and MCT1 SNPs were selected based on three criteria: (1) minor allele frequency (MAF) in European populations higher than 0.15, (2) a functional effect on expression/protein structure predicted by the National Institute of Environmental Health Sciences SNP Function Prediction tool [36 (link)], and (3) lack of high linkage disequilibrium between the SNPs. Based on these criteria, six SNPs (four in the gene coding for BSG and two in the gene coding for MCT1) were chosen. BSG and MCT1 SNP were determined using TaqMan SNP Genotyping (Applied Biosystems, Waltham, MA, USA) and LightSNiP (TIB MOLBIOL, Berlin, Germany) assays. PCR was performed on a LightCycler 480 II (Roche Diagnostics, Rotkreuz, Switzerland) according to the manufacturers’ protocols.
+ Open protocol
+ Expand
5

SNP Genotyping from Peripheral Blood

Check if the same lab product or an alternative is used in the 5 most similar protocols
Genomic DNA was extracted from peripheral blood leukocytes according to established protocols. Genotyping of SNPs was carried out by direct sequencing, TaqMan SNP genotyping (Applied Biosystems, Foster City, USA) or by primer extension of multiplex PCR products and subsequent allele detection by matrix-assisted laser desorption/ionization time of flight (MALDI-TOF; Sequenom, San Diego, USA). Direct sequencing was performed with the Big Dye Terminator Cycle sequencing kit version 1.1 (Applied Biosystems, Foster City, U.S.A.) according to the manufacturer’s instructions. Reactions were analyzed with an ABI Prism 3130xl sequencer (Applied Biosystems). TaqMan pre-designed SNP genotyping assays (Applied Biosystems) were used according to the manufacturer’s instructions. The rs144087548 variant was genotyped by polymerase chain reaction (forward primer: 5′-CGC AGA CAT GAT GCT GGG GGT-3′; reverse primer: 5′-ACA TGC AAG ACG GGG AAT TGA-3′) followed by HpyCH4III digestion (New England Biolabs, Ipswich, USA) and restriction fragment length analysis. All SNPs showed high genotyping quality with an average call rate >98 % in each of the five case–control samples.
+ Open protocol
+ Expand
6

NOD2 Genotyping in Healthy Individuals

Check if the same lab product or an alternative is used in the 5 most similar protocols
Informed consent was obtained per protocol approved by Yale University IRB. We performed genotyping by TaqMan SNP genotyping (Applied Biosystems, Foster City, CA) or Sequenom platform (Sequenom Inc., San Diego, CA). We utilized cells from healthy individuals not homozygous for R702W, G908R or Leu1007insC NOD2 mutations.
+ Open protocol
+ Expand
7

SNP Genotyping Using TaqMan Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

De novo genotyping of the SNP rs7806429 was done using the TaqMan SNP Genotyping assays according to the manufacturer's protocol (Applied Biosystems, Inc., Foster City, CA). To validate the reproducibility of genotyping, a random subset (about 5%) of the sample was re-genotyped; all genotypes matched initial designated genotypes. No deviations from HWE were observed (p>0.1).
+ Open protocol
+ Expand
8

Genotyping of Doxorubicin-Associated Variants

Check if the same lab product or an alternative is used in the 5 most similar protocols
Genomic DNA was isolated from EDTA blood samples with the QIAamp DNA Blood Kit (Qiagen). Saliva was collected with the Oragene DNA collection kit (DNA Genotec), and genomic DNA was extracted from saliva samples using the prepIT L2P reagent (DNA Genotec). DNA was quantified by Quant-iT PicoGreen assay (Invitrogen), according to the manufacturer’s protocols. Genomic DNA samples were genotyped for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 rs17863783 (Table 2) by TaqManSNP genotyping (Applied Biosystems), using the Type-it Fast SNP Probe PCR Kit (Qiagen) with predesigned primers and probes (Applied Biosystems).
Laboratory assistants were blinded to the case-control status of the patients genotyped in the study. To ensure the accuracy of all genotyping results, multiple positive and negative controls and replicate samples were included in all genotyping assays and plates. The concordance of genotype calls between replicate genotyped samples was 100%.
Genomic DNA will also be used to replicate the association of doxorubicin-related cardiovascular toxicity with other candidate genes that have been described [22 (link)] or that will be discovered in the future, provided our sample size is sufficient.
+ Open protocol
+ Expand
9

Genotyping PTPN22 and HLA-A from Blood

Check if the same lab product or an alternative is used in the 5 most similar protocols
DNA extraction from whole blood was performed using the DNeasy Blood and Tissue kit (Qiagen). PTPN22 C1858T genotype on all subjects was determined by TaqMan SNP Genotyping (Applied Biosystems). HLA-A genotype was determined through PCR amplification [32 (link)], purification of PCR product using QIAquick PCR Purification Kit (Qiagen), and Sanger sequencing. HLA-A type was determined by BLAST of PCR sequence against the IMGT/HLA database.
+ Open protocol
+ Expand
10

Inflammatory Bowel Disease Genetics

Check if the same lab product or an alternative is used in the 5 most similar protocols
Informed consent was obtained per protocol approved by the institutional review board at Yale University. For cell studies in healthy controls, we recruited participants with no personal or family history of autoimmune/inflammatory disease, including psoriasis, SLE, rheumatoid arthritis, multiple sclerosis, type I diabetes mellitus, CD, and ulcerative colitis, or a history of HIV. Due to the limitation in primary human cells and the range of stimulation conditions we wished to interrogate, two separate cohorts of 100 and 98 individuals were recruited for NOD2 and TLR2 dose-response studies, and NOD2 and TLR synergy studies in MDDC, respectively. Genotyping for polymorphisms was performed by TaqMan SNP genotyping (Applied Biosystems, Foster City, CA) or Sequenom platform (Sequenom Inc., San Diego, CA). For association studies, a total of 2724 subjects were enrolled, including 1512 CD cases (542 ileal, 705 ileocolonic and 265 colonic cases) and 1212 healthy controls. CD patients were diagnosed by clinical, endoscopic, radiologic and histologic criteria. Medical histories were collected with the validated NIDDK IBD Genetics Consortium phenotype forms (Nguyen et al., 2006 (link)).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!